All Drugs
Other · Aminosalicylate — anti-inflammatory agent acting locally on colonic mucosa (unclear mechanism — inhibits NF-κB, COX, LOX)

Pentasa (Mesalamine (5-Aminosalicylic Acid / 5-ASA))

Also sold as: Pentasa, Asacol, Mesacol, Mesasal, Salofalk

Pregnancy

Cat B

Lactation

Caution

Schedule

H

Forms

Tablet CR/SR 400mg, 500mg, 800mg +4

Indications

Adult Dosing

UC — mild-moderate acute flare (induction)

2.4–4.8 g/day PO in divided doses (or once daily with MR formulations)

Higher doses (4.8 g) for more active disease. Rectal mesalamine (suppository 1g OD or enema 2–4g OD) preferred for left-sided/rectal disease — combination oral + rectal superior to either alone.

UC — maintenance of remission

1.2–2.4 g/day PO (once daily preferred for adherence)

Continuous lifelong — stopping increases relapse risk

Proctitis/left-sided colitis (rectal)

Suppository 1g OD (proctitis) or Enema 2–4g OD at bedtime (left-sided)

Induction 6–8 weeks; maintenance ongoing

Maximum daily dose: 4.8 g/day (induction); 2.4 g/day (maintenance)

Pediatric Dosing

Age Range: ≥6 years (Pentasa granules); ≥12 years (tablets)
Dose: 30–50 mg/kg/day in 2 divided doses. Maintenance: 15–30 mg/kg/day (max 2g/day paediatric maintenance).

Granules can be mixed with soft food for younger children

Renal Dose Adjustment

CrCl / eGFRDose Adjustment
CrCl < 30 mL/minAvoid — risk of nephrotoxicity (interstitial nephritis); rectal formulations safer but still use with caution
Calculate eGFR / CrCl →

Hepatic Adjustment

No specific adjustment — hepatic and colonic acetylation; monitor LFTs

Pregnancy & Lactation

Pregnancy: Category B

Mesalamine is the preferred drug for maintaining UC remission in pregnancy. Uncontrolled UC is far more harmful to pregnancy than the drug. Avoid suppositories containing dibutyl phthalate (DBP — some older brands); use DBP-free formulations in pregnancy. Generally considered safe.

Lactation: Caution

Mesalamine and its metabolite (Ac-5-ASA) are excreted in breast milk. Risk of neonatal diarrhoea reported. Generally considered acceptable (especially oral formulations) but monitor infant for loose stools. Rectal formulations: very low systemic absorption — preferable during breastfeeding.

Top Drug Interactions

Interacting DrugEffectSeverity
Azathioprine / 6-mercaptopurineMesalamine inhibits TPMT enzyme — increases azathioprine/6-MP levels and bone marrow toxicity risk; monitor FBC closelyMajor
WarfarinPossible increased anticoagulant effect — monitor INRModerate
Lactulose / acidic medicationsMay disrupt pH-dependent release of some mesalamine formulations (Asacol — releases at pH > 7)Minor

DoctorScribe — AI Medical Scribe

Stop looking up Pentasa — just speak the prescription

"Pentasa as per dose, BD for 5 days." DoctorScribe writes the full prescription with brand, strength, frequency, and route — auto-applies pediatric weight-based dosing and renal adjustments. Try the live demo.

Side Effects

Common

  • Headache
  • Nausea
  • Abdominal pain
  • Diarrhoea (paradoxical worsening — usually settles)
  • Rash
  • Arthralgia

Serious / Discontinue If

  • Interstitial nephritis (rare but serious — monitor creatinine; renal biopsy if creatinine rises)
  • Mesalamine-induced acute intolerance syndrome (5% — worsening of colitis symptoms, fever, rash — can mimic flare; stop mesalamine)
  • Cardiac toxicity (myocarditis, pericarditis — rare)
  • Blood dyscrasias (rare — leucopenia, agranulocytosis)

Contraindications

Available Indian Brands

BrandManufacturerPrice (approx)
Pentasa 500mg CRFerring India50 tab ₹895
Mesacol 400mgSun Pharma30 tab ₹285
Salofalk 500mgDr Falk Pharma/Elder India30 tab ₹565
Mesasal 250mgCipla30 tab ₹185

Monitoring Required

Patient Counseling Points

Stop Googling drug references mid-consultation

EasyClinic auto-flags Pentasa interactions, renal cutoffs, and pregnancy warnings the moment you write the prescription. Built-in safety net for every Indian doctor.

Start 7-Day Free Trial

Clinically reviewed by: Dr. Pradeep Nair, DM (Gastroenterology), Consultant Gastroenterologist

Last reviewed: 2026-04-01

References

  • ECCO UC Guidelines 2022
  • AGA Ulcerative Colitis Management Guidelines 2020
  • BSG IBD Guidelines 2019
  • BNF — Mesalamine
  • Indian Society of Gastroenterology IBD Guidelines
Disclaimer: This information is for clinical reference only. It is not exhaustive and does not substitute clinical judgement. Always verify current dosing against the manufacturer's prescribing information and current treatment guidelines. Drug prices are approximate and may vary.